<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839653</url>
  </required_header>
  <id_info>
    <org_study_id>SDDMEDSI2021</org_study_id>
    <nct_id>NCT04839653</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria</brief_title>
  <official_title>Efficacy and Safety of Selective Digestive Decontamination in the ICU With Rates of Antibiotic-resistant Bacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDSI Clinical Hospital 1, ICU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDSI Clinical Hospital 1, ICU</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Secondary infections remain a major cause of mortality in critically ill patients, mainly&#xD;
      because of high prevalence of multidrug-resistant microorganisms. Therefore strategies aimed&#xD;
      to reduce the incidence of ventilator-associated pneumoniae (VAP) and bloodstream infections&#xD;
      are of utmost important. There is robust data on selective digestive decontamination (SDD)&#xD;
      efficacy in reduction of secondary infections in intensive care units (ICU) with low rates of&#xD;
      antibacterial resistance. However the data received from hospitals with moderate-to-high&#xD;
      rates of resistance is equivocal.&#xD;
&#xD;
      This as an interventional parallel open-label study investigating the effect of selective&#xD;
      digestive decontamination on the rates of ventilator-associated pneumonia in critically ill&#xD;
      patients admitted to the ICU with high prevalence of drug-resistant bacteria. Secondary&#xD;
      outcomes include rates of bloodstream infections, mortality, duration of mechanical&#xD;
      ventilation, duration of ICU stay, resistance selection and overall antibiotic consumption.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center prospective interventional parallel study. During the first period of the study&#xD;
      patients will receive standard therapy. During the second period the SDD protocol will be&#xD;
      implemented in addition to the standard care. The first period will end at the moment of the&#xD;
      last admitted patient ICU discharge or death.&#xD;
&#xD;
      Study population: general ICU adult patients anticipated to receive prolonged mechanical&#xD;
      ventilation (more than 48 hours). Patients who are terminally ill and are anticipated to die&#xD;
      in the next 24 hours will be excluded, so are patients with malignancies (except for patients&#xD;
      with primary central nervous system tumors who received radical treatment) and patients&#xD;
      admitted from other hospitals who received mechanical ventilation (including non-invasive&#xD;
      ventilation) for more than 24 hours.&#xD;
&#xD;
      Patients in the interventional arm will receive the following SDD protocol:&#xD;
&#xD;
        1. Oral paste (0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of&#xD;
           amphotericine B/500000 U of nistatin q6h&#xD;
&#xD;
        2. In the nasogastric tube (NGT) 10 ml of suspension containing 100 mg of polymyxin B, 80&#xD;
           mg of gentamycin, 350 mg of amphotericine B/8000000 U of nistatin and 500 mg of&#xD;
           vancomycin q6h&#xD;
&#xD;
        3. A 3-day course of intravenous cefotaxime 1 g q6h/ceftriaxone 1 qd&#xD;
&#xD;
      Statistical considerations and recruitment plant: VAP incidence in the ICU with high rates of&#xD;
      antibacterial resistance is 16,7 event per 1000 days of MV. To reveal a 25% decrease of VAP&#xD;
      events (power 80%, p &lt; 0,05) the study should recruit 25 patients in each group. However&#xD;
      because of the poor prognosis in mechanically ventilated elderly patients especially in the&#xD;
      setting of acute respiratory distress syndrome the goal is to recruit in each arm at least 25&#xD;
      patients younger than 65 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>During the first period patients will receive standard care. During the second period SDD protocol will be implemented.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of ventilator-associated pneumonia</measure>
    <time_frame>During ICU stay up to 28 days</time_frame>
    <description>Number of ventilator-associated pneumonia events per 1000 days of MV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of bloodstream infections</measure>
    <time_frame>During ICU stay up to 28 days</time_frame>
    <description>Number of bloodstream infection events per 1000 days of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>During ICU stay up to 28 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>During ICU stay up to 28 days</time_frame>
    <description>The duration that the patient receives mechanical ventilation in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of organ support</measure>
    <time_frame>During ICU stay up to 28 days</time_frame>
    <description>The duration that the patient receives mechanical ventilation, vasopressor infusion or renal-replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antimicrobial drug consumption</measure>
    <time_frame>During ICU stay up to 28 days</time_frame>
    <description>Average antimicrobial drug consumption (as daily defined doses) per patient stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antimicrobial resistance selection</measure>
    <time_frame>During ICU stay up to 28 days</time_frame>
    <description>The magnitude of antimicrobial resistance selection in terms of resistant microorganisms prevalence and whole burden of AMR genes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <condition>Pneumonia</condition>
  <condition>Bloodstream Infection</condition>
  <condition>Sepsis</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Respiratory Tract Infections</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Control group: standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the standard care group will be prospectively evaluated to determine pre-defined clinical outcomes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective digestive decontamination group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral paste (0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B q6h&#xD;
In the NGT 10 ml of suspension containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B and 500 mg of vancomycin q6h&#xD;
A 3-day course of intravenous cefotaxime 1 g q6h/ceftriaxone 1 qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h</intervention_name>
    <description>The oral paste will be applied topically on the oropharyngeal mucosa q6h.</description>
    <arm_group_label>Selective digestive decontamination group</arm_group_label>
    <other_name>Polymyxin B, Gentamycin, Amphotericine B, Nistatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h</intervention_name>
    <description>The suspension will be administered through the nasogastric tube q6h.</description>
    <arm_group_label>Selective digestive decontamination group</arm_group_label>
    <other_name>Polymyxin B, Gentamycin, Amphotericine B, Vancomycine, Nistatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd</intervention_name>
    <description>Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic</description>
    <arm_group_label>Selective digestive decontamination group</arm_group_label>
    <other_name>Cefotaxime, Ceftriaxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with expected MV for more than 24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Moribund condition and expected death within 24 hours&#xD;
&#xD;
          -  Malignancy (excluding primary CNS tumors)&#xD;
&#xD;
          -  Patients transferred from other hospitals who were mechanically ventilated for more&#xD;
             than 24 hours (including NIV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitry Azovskiy, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEDSI Clinical Hospital 1</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yury Surovoy, MD</last_name>
    <phone>+79166911507</phone>
    <email>ysurovoy@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Armen Oganesyan, MD</last_name>
    <email>oganesyan.av@medsigroup.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MEDSI Clinical Hospital 1</name>
      <address>
        <city>Moscow</city>
        <zip>143442</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armen Oganesyan</last_name>
      <email>oganesyan.av@medsigroup.ru</email>
    </contact>
    <contact_backup>
      <last_name>Yury Surovoy</last_name>
      <email>ysurovoy@gmail.co</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MEDSI Clinical Hospital 1, ICU</investigator_affiliation>
    <investigator_full_name>Yury Surovoy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Ventilator-Associated Pneumonia</keyword>
  <keyword>Selective Digestive Decontamination</keyword>
  <keyword>Secondary Infections</keyword>
  <keyword>Infection prophylaxis</keyword>
  <keyword>Bloodstream Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

